Rehmannia Glutinosa Root

Dosage for Rehmannia Glutinosa Root extract is not measured in milligrams like standard pharmaceuticals but is instead expressed in Weight/Volume (w/v) ratios or Protein Nitrogen Units (PNU/mL).

• Skin Prick Testing: Typically, a concentration of 1:10 or 1:20 w/v is used. A single drop (approximately 0.05 mL) is applied to the skin, and a sterile lancet is used to prick the epidermis.
• Intradermal Testing: If the prick test is negative but clinical suspicion remains high, an intradermal injection of 0.02 to 0.05 mL of a 1:1000 w/v or 1:100 w/v solution may be administered.
• Immunotherapy: Dosing begins with an extremely dilute 'maintenance' concentrate (e.g., 1:100,000 w/v) and is increased weekly by 0.05 to 0.1 mL until a maintenance dose is reached, usually 0.5 mL of a 1:100 or 1:20 w/v solution.

Rehmannia Glutinosa Root allergenic extracts can be used in children, but extreme caution is required.

• Infants (<1 year): Skin testing is generally avoided unless strictly necessary, as skin reactivity is lower and the risk of systemic reactions is higher.
• Children (1-12 years): Dosing follows the same volume protocols as adults (0.02-0.05 mL), but healthcare providers often use more dilute concentrations for initial testing to minimize the risk of a systemic reaction.
• Adolescents: Standard adult concentrations are typically well-tolerated.

Renal Impairment

No specific dosage adjustments are required for localized skin testing in patients with renal impairment. However, if the patient is undergoing systemic immunotherapy, the healthcare provider should monitor for delayed clearance of inflammatory mediators if a reaction occurs.

Hepatic Impairment

No adjustments are necessary for diagnostic testing. The metabolic load of a skin test is negligible and does not tax hepatic function.

Elderly Patients

In patients over 65, skin reactivity (the 'wheal' response) may be diminished due to age-related changes in skin turgor and mast cell density. Healthcare providers may need to interpret 'borderline' results with caution or consider blood-based IgE testing (e.g., RAST or ImmunoCAP).

Rehmannia Glutinosa Root extract is strictly for professional use and is never self-administered by the patient at home for diagnostic purposes.

• Preparation: The skin (usually the forearm or back) is cleaned with alcohol and allowed to dry.
• Application: Drops are placed at least 2-3 cm apart to prevent overlapping reactions.
• Observation: The patient must remain in the clinic for at least 30 minutes following administration to monitor for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Freezing must be avoided as it denatures the allergenic proteins, rendering the extract ineffective.

In the context of diagnostic testing, a 'missed dose' simply means the test must be rescheduled. For patients on an immunotherapy schedule:

• If a dose is missed by 1-7 days, the previous dose is usually repeated.
• If missed by more than 2 weeks, the dose may need to be reduced significantly to avoid a 're-priming' effect that could lead to a systemic reaction.

An 'overdose' in allergy testing occurs if too much extract is injected or if the concentration is too high for the patient's sensitivity level.

• Signs: Massive local swelling (greater than 10 cm), generalized hives (urticaria), swelling of the throat (angioedema), wheezing, or a drop in blood pressure.
• Emergency Measures: Immediate administration of Epinephrine (0.3 mg IM for adults), followed by antihistamines and corticosteroids. The patient may require oxygen and intravenous fluids.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to use these extracts without professional medical guidance.

The most frequent side effects of Rehmannia Glutinosa Root extract are localized to the site of administration. These are often expected outcomes of the diagnostic process:

• Pruritus (Itching): Intense itching at the test site is the most common symptom, usually beginning within 5 minutes and subsiding within 1-2 hours.
• Wheal Formation: A raised, pale bump resembling a mosquito bite. This is the primary indicator of a positive test.
• Erythema (Redness): A 'flare' or redness surrounding the wheal, caused by localized vasodilation.
• Local Tenderness: The area may feel warm or slightly sore for several hours after the test.

• Delayed Local Reactions: Some patients experience swelling and redness at the site 6 to 24 hours after the test. This is typically a Type IV (cell-mediated) hypersensitivity response and should be reported to the doctor.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit if the forearm was tested).
• Fatigue: A general feeling of tiredness following the immune system's activation during the test.

• Vasovagal Syncopy: Fainting or lightheadedness, often triggered by the needle prick rather than the extract itself.
• Persistent Granuloma: A small, hard knot at the injection site that may last for weeks.
• Systemic Urticaria: Hives appearing on parts of the body far away from the test site.

> Warning: Stop the procedure and call for emergency help if you experience any of the following symptoms of anaphylaxis.

• Angioedema: Rapid swelling of the lips, tongue, or throat which can obstruct the airway.
• Bronchospasm: Sudden wheezing, chest tightness, or difficulty breathing.
• Hypotension: A sharp drop in blood pressure, leading to dizziness, confusion, or loss of consciousness.
• Tachycardia: A rapid or pounding heartbeat as the body reacts to systemic histamine release.
• Gastrointestinal Distress: Sudden, severe abdominal cramping, vomiting, or diarrhea immediately following the injection.

While diagnostic testing rarely has long-term effects, repeated exposure through immunotherapy can lead to:

• Increased Sensitivity: In rare cases, the test itself can 'sensitize' a previously non-allergic patient, though this is clinically debated.
• Subcutaneous Atrophy: Thinning of the skin or fat at the site of repeated immunotherapy injections.

No FDA black box warnings for Rehmannia Glutinosa Root specifically, but all allergenic extracts carry a general class warning regarding Anaphylaxis. The warning states that these products can cause severe, life-threatening systemic reactions. They must only be administered by healthcare providers prepared to treat anaphylaxis, and patients must be observed for at least 30 minutes post-injection.

Report any unusual symptoms, especially those occurring hours after leaving the clinic, to your healthcare provider immediately.

Rehmannia Glutinosa Root extract is a potent biological agent. Its use is restricted to clinical settings equipped with 'crash carts' containing epinephrine, oxygen, and airway management tools. Patients should be in a stable state of health before undergoing testing or treatment. If you are suffering from an acute infection, a fever, or an asthma flare-up, your appointment should be postponed, as these conditions can lower the threshold for a severe systemic reaction.

As of 2024, the FDA does not mandate a specific black box warning for Rehmannia Glutinosa Root, but the class-wide warning for allergenic extracts is strictly enforced. This warning emphasizes that systemic reactions are unpredictable and can occur even in patients who have previously tolerated the extract. The risk is significantly higher in patients with unstable asthma or those taking certain medications like beta-blockers.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Healthcare providers must perform a 'graded' test, starting with a skin prick before moving to intradermal injections.
• Asthma Status: Patients with severe or poorly controlled asthma (FEV1 < 70% of predicted) are at a much higher risk for fatal reactions during allergy testing. Asthma must be stable for at least 48 hours prior to testing.
• Cardiovascular Disease: Patients with pre-existing heart conditions may not be able to tolerate the physiological stress of a systemic reaction or the epinephrine used to treat it.
• Autoimmune Disorders: There is a theoretical risk that stimulating the immune system with allergenic extracts could exacerbate certain autoimmune conditions.

• Immediate Observation: Patients must remain under direct medical supervision for 30 minutes.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after testing to ensure no bronchoconstriction has occurred.
• Site Inspection: The healthcare provider must measure the diameter of the wheal and flare in millimeters and record it in the patient's permanent medical record.

Generally, Rehmannia Glutinosa Root extract does not cause drowsiness. However, if a systemic reaction occurs and antihistamines (like diphenhydramine) are administered, the patient will be significantly impaired and should not drive or operate machinery for at least 24 hours.

Alcohol should be avoided for 24 hours before and after allergy testing. Alcohol increases blood flow to the skin (vasodilation), which can lead to 'false positive' results or accelerate the absorption of the allergen into the bloodstream, increasing the risk of a systemic reaction.

There is no withdrawal syndrome associated with Rehmannia Glutinosa Root extract. However, if a patient stops an immunotherapy program prematurely, they will lose any accumulated desensitization and will remain fully allergic to the substance.

> Important: Discuss all your medical conditions, especially respiratory or heart issues, with your healthcare provider before starting Rehmannia Glutinosa Root testing.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These are strictly contraindicated in many allergy clinics. If a patient on a beta-blocker has an anaphylactic reaction to Rehmannia extract, the beta-blocker prevents epinephrine from working effectively. This can lead to 'epinephrine-resistant anaphylaxis,' which is often fatal.
• Inhaled/Systemic Corticosteroids (High Dose): While not always contraindicated, high doses can suppress the immune response so significantly that the allergy test yields a 'false negative,' leading to a missed diagnosis.

• ACE Inhibitors (e.g., Lisinopril): These medications can interfere with the body's ability to degrade kinins, potentially worsening the severity of an allergic reaction or angioedema.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine if it must be used to treat a reaction, leading to dangerous spikes in blood pressure.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular risks associated with emergency epinephrine administration.

• Antihistamines (H1 Blockers): Medications like loratadine (Claritin), cetirizine (Zyrtec), and diphenhydramine (Benadryl) must be stopped 3 to 7 days before testing. They block the H1 receptors on skin blood vessels, preventing the wheal and flare reaction and making the test results invalid.
• H2 Blockers (e.g., Famotidine): These can also partially suppress skin reactivity and should be discontinued 48 hours prior to testing.

• Caffeine: High intake of caffeine on the day of testing can cause jitteriness and tachycardia, which may be confused with the early signs of a systemic allergic reaction.
• High-Fat Meals: There is no direct interaction, but heavy meals can cause gastrointestinal discomfort that complicates the assessment of systemic symptoms.

• St. John's Wort: May affect the metabolism of any emergency medications used.
• Licorice Root: Can affect electrolyte balance and blood pressure, potentially complicating the management of a systemic reaction.
• Rehmannia Supplements: If the patient is taking oral Rehmannia supplements, they must inform their doctor, as this significantly increases the risk of a severe reaction during skin testing due to 'pre-loading' the immune system.

Rehmannia Glutinosa Root extract does not typically interfere with standard blood chemistry or hematology tests. However, it will directly interfere with:

• Skin Reactivity Tests: Using other plant extracts simultaneously may lead to cross-contamination or suppressed results if the sites are too close.
• Serum Tryptase: If a systemic reaction occurs, serum tryptase levels will be elevated, which is used as a diagnostic marker for mast cell degranulation.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'heart' or 'blood pressure' pills.

Rehmannia Glutinosa Root extract must NEVER be used in the following circumstances:

• Previous Anaphylaxis to Rehmannia: If a patient has a documented history of life-threatening reactions to this specific root or its extracts, further testing is strictly prohibited.
• Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) below 70% of their predicted value are at extreme risk for fatal bronchospasm during testing.
• Acute Dermographism: A condition where the slightest scratch causes a hive. In these patients, the 'prick' itself will cause a wheal, making it impossible to interpret the allergy test.
• Active Skin Disease: Testing cannot be performed on skin with active eczema, psoriasis, or infection at the site of application.

Conditions requiring a careful risk-benefit analysis by the allergist:

• Pregnancy: While not directly toxic, the risk of a systemic reaction (and the subsequent hypoxia or epinephrine use) poses a significant threat to the fetus.
• Beta-Blocker Therapy: If the patient cannot safely stop their beta-blocker, the doctor may opt for a blood test (In Vitro) rather than a skin test.
• Malignancy or Severe Immunodeficiency: The immune system may not respond predictably to the extract.

Patients allergic to other members of the Scrophulariaceae (Figwort) family may show cross-reactivity. This includes plants like Digitalis (Foxglove) and Verbascum (Mullein). If you have had a reaction to these plants, notify your healthcare provider before testing with Rehmannia.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of fainting or severe allergies, before prescribing this extract.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Rehmannia Glutinosa Root extract in pregnant women. Animal reproduction studies have not been conducted. The primary risk during pregnancy is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis). Anaphylaxis in the mother can cause uterine contractions, placental abruption, and fetal hypoxia (lack of oxygen). Most allergists recommend postponing diagnostic skin testing until after delivery. Immunotherapy should generally not be initiated during pregnancy, though 'maintenance' doses may sometimes be continued if the risk of stopping is higher than the risk of continuing.

It is not known whether the allergenic proteins or glycosides of Rehmannia are excreted in human milk. Because the amount of extract used in skin testing is so small, the risk to a nursing infant is considered negligible. However, as a precaution, mothers should monitor their infants for any signs of hives or irritability if the mother underwent testing or received an immunotherapy injection.

Rehmannia extract is safe for use in children when administered by a specialist. However, the 'pain' of the skin prick can be distressing. For very young children, clinicians may use 'multi-test' devices that apply several allergens at once with minimal discomfort. It is important to note that children have smaller blood volumes, so a systemic reaction can progress more rapidly than in an adult.

In patients over 65, the skin is often thinner and less reactive. This can lead to 'false negative' results. Furthermore, elderly patients are more likely to be taking medications (like beta-blockers or ACE inhibitors) that increase the risk of a severe reaction. A thorough review of the patient's medication list is mandatory before testing.

No dosage adjustments are needed for the diagnostic use of Rehmannia extract in patients with kidney disease. The systemic exposure is insufficient to cause renal stress or require altered dosing.

Similar to renal impairment, hepatic dysfunction does not affect the safety or efficacy of localized skin testing. The liver's role in processing the minute amounts of protein in a skin test is minimal.

> Important: Special populations, particularly pregnant women and the elderly, require individualized medical assessment and a cautious approach to allergy testing.

Rehmannia Glutinosa Root extract acts as a complex poly-antigenic stimulus. The primary molecular mechanism involves the binding of Rehmannia-specific proteins to IgE antibodies fixed on the surface of mast cells. This triggers the Syk-kinase pathway within the mast cell, leading to the release of histamine from intracellular granules. Histamine then binds to H1 receptors on local vascular endothelial cells, causing them to contract and leak fluid (edema/wheal), and on sensory nerve endings, causing itching.

• Onset of Action: The wheal and flare reaction typically begins within 5 minutes of administration.
• Peak Effect: The maximum reaction size is usually reached between 15 and 20 minutes.
• Duration: The visible reaction generally fades within 2 to 4 hours, though a 'late-phase' reaction (swelling) can occur 6-12 hours later in sensitive individuals.

| Parameter | Value |

|---|---|

| Bioavailability | <1% (Percutaneous) |

| Protein Binding | 30-50% (Constituents) |

| Half-life | 2-4 hours (Catalpol) |

| Tmax | 15-20 minutes (Local) |

| Metabolism | Hepatic/Microbial |

| Excretion | Renal 70%, Fecal 30% |

The root contains over 70 bioactive compounds, including:

• Iridoid Glycosides: Catalpol, Rehmanniosides A, B, C, and D.
• Phenethyl Alcohol Glycosides: Acteoside and Isoacteoside.
• Polysaccharides: Rehmannan-SA and SB.
• Molecular Formula (Catalpol): C15H22O10
• Molecular Weight (Catalpol): 362.33 g/mol

Rehmannia Glutinosa Root is classified as a Non-Standardized Plant Allergenic Extract. It is grouped with other botanical extracts like Oak, Ragweed, and Grass extracts used in clinical immunology. Unlike 'Standardized' extracts (like Honey Bee Venom), its potency is determined by the weight of the raw material used in extraction rather than a biological assay of a specific allergen.